Shattuck Labs (STTK) Registration Filing summary

Company overview and business model

• Specializes in developing treatments for inflammatory and immune-mediated diseases, with a focus on a first-in-class antibody for inflammatory bowel disease and related conditions.

• Lead program, SL-325, is a death receptor 3 antagonist antibody, leveraging expertise in protein engineering and TNF receptor therapeutics.

• Incorporated in Delaware in 2016, with principal offices in Austin, TX.

Risk factors and disclosures

• Faces risks related to clinical trial timing, patient enrollment, R&D costs, regulatory approvals, and commercialization.

• Exposed to market, competitive, and macroeconomic risks, including inflation, economic downturns, and public health crises.

• Risks and uncertainties are detailed in incorporated SEC filings, including annual and quarterly reports.

Use of proceeds and capital allocation

• Net proceeds will be used to advance clinical trials, develop additional product candidates, and for working capital and general corporate purposes.

• May allocate funds to license, acquire, or invest in complementary businesses or technologies, though no current commitments exist.

• Pending use, proceeds may be invested in capital preservation instruments.